Ńjẹ́rìísi...
A túmọ̀ rẹ̀ láìfọwọ́yí. Fún ìwọ̀n oògùn àti ìkìlọ̀: wo ẹ̀dà Gẹ̀ẹ́sì àkọ́kọ́. Ka ní Gẹ̀ẹ́sì
Ilé / Ìforúkọsílẹ̀ ní Nàìjíríà / Derm's Cimetidine Tablet

Derm's Cimetidine Tablet

NAFDAC Reg. Rárá. C4-1846 · Oògùn

Forukọsilẹ pẹlu NAFDAC. Iforukọsilẹ ti nṣiṣe lọwọAs of 6 November 2026 · synced automatically from official sources.
Ọja
Derm's Cimetidine Tablet
Nọmba NAFDAC
C4-1846
Ohun elo ti nṣiṣe lọwọ
Cimetidine
Agbara
400 mg
Fọọmu
Tablet
Iwọn iṣakojọpọ
1 x 20's
Olupese
Ko ṣe atokọ
Olubẹwẹ (oluranlowo)
Derm Pharmaceuticals Limited
Ti fọwọsi
28 Sep 2021
Ipò
Inactive Wo lórí NAFDAC ↗
Iforukọsilẹ wulo si
27 Sep 2026
Tani o ṣe itaniji
Kosi ikankan ti a rii.
Ijabọ Agbegbe
Kò sí
Àwọn àyẹ̀wò àsìkò
0

Nipa oogun naa: Cimetidine: uses, dosage and brands worldwide

What we found

  • Derm's Cimetidine Tablet is on the NAFDAC register with an active registration (C4-1846). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Derm's Cimetidine Tablet

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Tani o jẹ fun

Cimetidine tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION: Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of cimetidine tablets and antacids is not recommended, since antacids have been reported to interfere with the absorption of cimetidine. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. …

Bii o ṣe le mu u ati igba melo ni
  • Duodenal Ulcer Active Duodenal Ulcer Clinical studies have indicated that suppression of nocturnal acid is the most important factor in duodenal ulcer healing (see CLINICAL PHARMACOLOGY: Antisecretory Activity: Acid Secretion )
  • This is supported by recent clinical trials (see CLINICAL TRIALS: Duodenal Ulcer: Active Duodenal Ulcer )
  • Therefore, there is no apparent rationale, except for familiarity with use, for treating with anything other than a once-daily at bedtime dosage regimen
  • In a U.S. dose-ranging study of 400 mg at bedtime, 800 mg at bedtime and 1600 mg at bedtime, a continuous dose-response relationship for ulcer healing was demonstrated
  • However, 800 mg at bedtime is the dose of choice for most patients, as it provides a high healing rate (the difference between 800 mg at bedtime and 1,600 mg at bedtime being small), maximal pain relief, a decreased potential for drug interactions (see PRECAUTIONS: Drug Interactions ) and maximal patient convenience
  • Patients unhealed at 4 weeks, or those with persistent symptoms, have been shown to benefit from 2 to 4 weeks of continued therapy
  • It has been shown that patients who both have an endoscopically demonstrated ulcer larger than 1.0 cm and are also heavy smokers (i.e., smoke 1 pack of cigarettes or more per day) are more difficult to heal
  • There is some evidence which suggests that more rapid healing can be achieved in this subpopulation with 1,600 mg of cimetidine tablets at bedtime. …
Talk to a doctor first if

Cimetidine tablets are contraindicated for patients known to have hypersensitivity to the product.

Warnings

PRECAUTIONS General Rare instances of cardiac arrhythmias and hypotension have been reported following the rapid administration of cimetidine hydrochloride injection by intravenous bolus. Symptomatic response to treatment with cimetidine tablets do not preclude the presence of a gastric malignancy. There have been rare reports of transient healing of gastric ulcers despite subsequently documented malignancy. Reversible confusional states (see ADVERSE REACTIONS ) have been observed on occasion, predominantly, but not exclusively, in severely ill patients. Advancing age (50 or more years) and preexisting liver and/or renal disease appear to be contributing factors. …

Àbájáde tí ó ṣeéṣe

Adverse effects reported in patients taking cimetidine tablets are described as follows by body system. Incidence figures of 1 in 100 and greater are generally derived from controlled clinical studies. Gastrointestinal Diarrhea (usually mild) has been reported in approximately 1 in 100 patients. CNS Headaches, ranging from mild to severe, have been reported in 3.5% of 924 patients taking 1,600 mg/day, 2.1% of 2,225 patients taking 800 mg/day and 2.3% of 1,897 patients taking placebo. Dizziness and somnolence (usually mild) have been reported in approximately 1 in 100 patients on either 1,600 mg/day or 800 mg/day. …

If you take too much

Studies in animals indicate that toxic doses are associated with respiratory failure and tachycardia that may be controlled by assisted respiration and the administration of a beta-blocker. Reported acute ingestions orally of up to 20 grams have been associated with transient adverse effects similar to those encountered in normal clinical experience. The usual measures to remove unabsorbed material from the gastrointestinal tract, clinical monitoring, and supportive therapy should be employed. …

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2023-08-18.

Label for cimetidine, the active ingredient registered with NAFDAC.

NAFDAC recall & alert notices

Public Alert No. 05/2026 – Alert on the Mop-up of Counterfeit Dermazin (1% Silver Sulphadiazine) Cream6 Feb 2026 · nafdac.gov.ngThe National Agency for Food and Drug Administration and Control (NAFDAC) is alerting healthcare providers and the public about the circulation of counterfeit Dermazin (1% Silver Sulphadiazine) Cream.NAFDAC received a complaint from the legitimate Marketing Authorization Holder, Taylek Drugs Company Limited, concerning…Public Alert No. 005/2022- Recall of Dermaved Sensitive Cream (Unlicensed Medicine)10 Feb 2022 · nafdac.gov.ng, The National Agency for Food and Drug Administration and Control is informing healthcare providers that Medicines & Healthcare products Regulatory Agency (MHRA) in conjunction with Dermaved is recalling Dermaved Sensitive Cream due to presence of clobetasol propionate (0.001% w/w).   Clobetasol propionate is a strong…Public Alert No. 028/2020- Boots Company PLC Recalls Boots Dermacare 1% w/w Hydrocortisone Ointment, EL (20) A/47 (Batch Number: IDD) due to the presence of Pseudomonas aeruginosa12 Nov 2020 · nafdac.gov.ng, The National Agency for Food and Drug Administration and Control has been informed by the United Kingdom’s (UK) Medicine and Healthcare Product Regulatory Agency (MHRA) that Boots Company PLC has recalled Boots Dermacare 1% w/w Hydrocortisone Ointment, EL (20) A/47 (Batch Number: IDD) due to the presence of Pseudomon…

Compare the brands and batch numbers in these notices with your pack, or enter your batch number above.

Check your pack of Derm's Cimetidine Tablet

Add the expiry date on your pack for a full Trust Score.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Derm's Cimetidine Tablet

What is in Derm's Cimetidine Tablet?

Derm's Cimetidine Tablet contains Cimetidine (400 mg), as tablet, according to its NAFDAC registration record.

Is Derm's Cimetidine Tablet registered with NAFDAC?

Yes. Derm's Cimetidine Tablet is listed on the NAFDAC register under registration number C4-1846, and its registration is active as of 6 November 2026.

Has Derm's Cimetidine Tablet been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Derm's Cimetidine Tablet in our automatically synced alert list.

How can I check that my pack of Derm's Cimetidine Tablet is genuine?

Run a free authenticity scan with the NAFDAC number C4-1846, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Derm's Cimetidine Tablet?

Follow your prescription or the leaflet in your pack. The official label says: Duodenal Ulcer Active Duodenal Ulcer Clinical studies have indicated that suppression of nocturnal acid is the most important factor in duodenal ulcer healing (see CLINICAL PHARMACOLOGY: Antisecretory Activity: Acid Secretion ). This is supported by recent clinical trials (see CLINICAL TRIALS: Duodenal Ulcer: Active Duodenal Ulcer ). Therefore, there is no apparent rationale, e…

What is Derm's Cimetidine Tablet used for?

Cimetidine tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION: Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of cimetidine tablets and an (Summarised from the official U.S. FDA label for cimetidine. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Derm's Cimetidine Tablet? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.